AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2017, Aeglea BioTherapeutics, Inc. issued a press
release announcing its financial results for the quarter ended
March 31, 2017. A copy of the press release is attached as
Exhibit 99.1 to this report.
The information in this Item 2.02, including Exhibit 99.1 to this
report, shall not be deemed to be filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended (the Securities Act).The information contained
in this Item 2.02 and in the accompanying Exhibit 99.1 shall not
be incorporated by reference into any other filing under the
Exchange Act or under the Securities Act, except as shall be
expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description |
|
99.1 |
Press release issued by Aeglea BioTherapeutics, Inc. |
About AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE)
Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria. AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) Recent Trading Information
AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) closed its last trading session down -0.20 at 6.37 with 17,203 shares trading hands.
